title: [Anti-TNF-α treatment for uveitis. Analysis of the current situation].
abstract: Biologicals are selectively acting proteins that demonstrated high efficacy in the treatment of chronic disorders. In particular, biologicals blocking tumor necrosis factor α (TNF-α), an essential cytokine in chronic inflammatory diseases, have demonstrated great promise. Experimental and clinical data indicate that TNF-α plays an important role in intraocular inflammation. Neutralization of TNF-α might therefore be a promising strategy for prevention and treatment of uveitis. Here we review the principle effects, therapeutic value, and potential side effects of anti-TNF agents in uveitis.
authors.affiliation: Universitäts-Augenklinik, Charité, Campus Virchow-Klinikum, Humboldt-Universität zu Berlin, Augustenburger Platz 1, 13353 Berlin. uwe.pleyer@charite.de
authors.forename: U
authors.initials: U
authors.lastname: Pleyer
authors.forename: F
authors.initials: F
authors.lastname: Mackensen
authors.forename: S
authors.initials: S
authors.lastname: Winterhalter
authors.forename: N
authors.initials: N
authors.lastname: Stübiger
mesh_terms: D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000276:immunology / Q000627:therapeutic use; D001688:Biological Products / Q000009:adverse effects* / Q000276:immunology / Q000627:therapeutic use*; D006801:Humans; D018448:Models, Immunological; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors* / Q000276:immunology*; D014605:Uveitis / Q000188:drug therapy* / Q000276:immunology*
chemical_list: D000911:Antibodies, Monoclonal; D001688:Biological Products; D014409:Tumor Necrosis Factor-alpha